Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study

Introduction:Pancreatic cancer is the seventh leading cause of cancer-related death worldwide, and surgical resection with radical intent remains the only potentially curative treatment option today. However, borderline resectable pancreatic ductal adenocarcinomas (BR-PDAC) stand in the gray area be...

ver descrição completa

Detalhes bibliográficos
Autores: Secanella Medayo, Luis, Busquets, Juli, Peláez, Núria, Sorribas, María, Laquente, Berta, Ruiz, Sandra, Carnaval, Thiago, Videla, Sebastià, Fabregat, Juan
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/192186
Acesso em linha:https://hdl.handle.net/2445/192186
Access Level:acceso abierto
Palavra-chave:Càncer de pàncrees
Cirurgia
Tractament adjuvant del càncer
Pancreas cancer
Surgery
Adjuvant treatment of cancer
id ES_d7ffc8176d7f6bbcee184a90cb0b2ed2
oai_identifier_str oai:recercat.cat:2445/192186
network_acronym_str ES
network_name_str España
repository_id_str
spelling Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort studySecanella Medayo, LuisBusquets, JuliPeláez, NúriaSorribas, MaríaLaquente, BertaRuiz, SandraCarnaval, ThiagoVidela, SebastiàFabregat, JuanCàncer de pàncreesCirurgiaTractament adjuvant del càncerPancreas cancerSurgeryAdjuvant treatment of cancerIntroduction:Pancreatic cancer is the seventh leading cause of cancer-related death worldwide, and surgical resection with radical intent remains the only potentially curative treatment option today. However, borderline resectable pancreatic ductal adenocarcinomas (BR-PDAC) stand in the gray area between the resectable and unresectable disease since they are technically resectable but have a high probability of incomplete exeresis. Neoadjuvant treatment (NAT) plays an important role in ensuring resection success.Different survival prognostic factors for BR-PDAC have been well described, but evidence on the predictive factors associated with resection after NAT is scarce. This study aims to study if CA 19-9 plasmatic levels and the tumor anatomical relationship with neighboring vascular structures are prognostic factors for resection and survival (both Overall Survival and Progression-Free Survival) in patients with type A BR-PDAC. Methods:This will be a retrospective cohort study using data from type A BR-PDAC patients who received NAT in the Bellvitge University Hospital. The observation period is from January 2010 until December 2019; patients must have a minimum 12-month follow-up. Patients will be classified according to the MD Anderson Cancer Center criteria for BR-PDAC. Discussion:Patients with BR-PDAC have a high risk for a margin-positive resection. Serum Carbohydrate Antigen 19-9 plasmatic levels and vascular involvement stand out as disease-related prognostic factors.This study will provide valuable information on the prognostic factors associated with resection. We will exclude locally advanced tumors and expect this approach to provide more realistic resection rates without selecting those patients that undergo surgical exploration. However, focusing on an anatomical definition may limit the results' generalizability.Ovid Technologies (Wolters Kluwer Health)2023202320222023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion6 p.application/pdfhttps://hdl.handle.net/2445/192186Articles publicats en revistes (Ciències Clíniques)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.1097/MD.0000000000032126Medicine, 2022, vol. 101, num. 48, p. e32126https://doi.org/10.1097/MD.0000000000032126cc by (c) Secanella, Luis et al., 2022http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1921862026-05-29T05:05:01Z
dc.title.none.fl_str_mv Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study
title Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study
spellingShingle Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study
Secanella Medayo, Luis
Càncer de pàncrees
Cirurgia
Tractament adjuvant del càncer
Pancreas cancer
Surgery
Adjuvant treatment of cancer
title_short Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study
title_full Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study
title_fullStr Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study
title_full_unstemmed Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study
title_sort Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study
dc.creator.none.fl_str_mv Secanella Medayo, Luis
Busquets, Juli
Peláez, Núria
Sorribas, María
Laquente, Berta
Ruiz, Sandra
Carnaval, Thiago
Videla, Sebastià
Fabregat, Juan
author Secanella Medayo, Luis
author_facet Secanella Medayo, Luis
Busquets, Juli
Peláez, Núria
Sorribas, María
Laquente, Berta
Ruiz, Sandra
Carnaval, Thiago
Videla, Sebastià
Fabregat, Juan
author_role author
author2 Busquets, Juli
Peláez, Núria
Sorribas, María
Laquente, Berta
Ruiz, Sandra
Carnaval, Thiago
Videla, Sebastià
Fabregat, Juan
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Càncer de pàncrees
Cirurgia
Tractament adjuvant del càncer
Pancreas cancer
Surgery
Adjuvant treatment of cancer
topic Càncer de pàncrees
Cirurgia
Tractament adjuvant del càncer
Pancreas cancer
Surgery
Adjuvant treatment of cancer
description Introduction:Pancreatic cancer is the seventh leading cause of cancer-related death worldwide, and surgical resection with radical intent remains the only potentially curative treatment option today. However, borderline resectable pancreatic ductal adenocarcinomas (BR-PDAC) stand in the gray area between the resectable and unresectable disease since they are technically resectable but have a high probability of incomplete exeresis. Neoadjuvant treatment (NAT) plays an important role in ensuring resection success.Different survival prognostic factors for BR-PDAC have been well described, but evidence on the predictive factors associated with resection after NAT is scarce. This study aims to study if CA 19-9 plasmatic levels and the tumor anatomical relationship with neighboring vascular structures are prognostic factors for resection and survival (both Overall Survival and Progression-Free Survival) in patients with type A BR-PDAC. Methods:This will be a retrospective cohort study using data from type A BR-PDAC patients who received NAT in the Bellvitge University Hospital. The observation period is from January 2010 until December 2019; patients must have a minimum 12-month follow-up. Patients will be classified according to the MD Anderson Cancer Center criteria for BR-PDAC. Discussion:Patients with BR-PDAC have a high risk for a margin-positive resection. Serum Carbohydrate Antigen 19-9 plasmatic levels and vascular involvement stand out as disease-related prognostic factors.This study will provide valuable information on the prognostic factors associated with resection. We will exclude locally advanced tumors and expect this approach to provide more realistic resection rates without selecting those patients that undergo surgical exploration. However, focusing on an anatomical definition may limit the results' generalizability.
publishDate 2022
dc.date.none.fl_str_mv 2022
2023
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/192186
url https://hdl.handle.net/2445/192186
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1097/MD.0000000000032126
Medicine, 2022, vol. 101, num. 48, p. e32126
https://doi.org/10.1097/MD.0000000000032126
dc.rights.none.fl_str_mv cc by (c) Secanella, Luis et al., 2022
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by (c) Secanella, Luis et al., 2022
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 6 p.
application/pdf
dc.publisher.none.fl_str_mv Ovid Technologies (Wolters Kluwer Health)
publisher.none.fl_str_mv Ovid Technologies (Wolters Kluwer Health)
dc.source.none.fl_str_mv Articles publicats en revistes (Ciències Clíniques)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421059599499264
score 15.81155

Registos relacionados